Nivolumab Combined With BMS-986253 in HCC Patients
Status:
Recruiting
Trial end date:
2024-08-05
Target enrollment:
Participant gender:
Summary
A phase II clinical trial is utilized to examine whether BMS-986253 (25 subjects) or
Cabiralizumab (25 subjects) when combined with Nivolumab offers improved radiographic
objective response rates (ORR) over Nivolumab monotherapy (25 subjects) in advanced HCC
patients.